The PIONEER TEENS trial compared oral semaglutide at maximum tolerated doses with placebo in adolescents aged 10 to 17 years with T2D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results